The membrane complement regulatory protein CD59 promotes tumor growth and predicts poor prognosis in breast cancer
| Autor: | Tianbao Huang, Na Wang, Yun Xia, Peipei Ding, Shan Li, Sheng Chen, Long Zhang, Fugui Ye, Rongcheng Luo, Zhiming Shao, Yiqun Du, Yi-Zhou Jiang, Chaoqun Yang, Weiguo Hu, Xiao-Jian Ni, Qianwen Ouyang, Liang Huang, Yujing Sun |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
0301 basic medicine Oncology Cancer Research medicine.medical_specialty Lung Neoplasms Cell Breast Neoplasms CD59 Antigens chemical and pharmacologic phenomena CD59 Biology Mice 03 medical and health sciences 0302 clinical medicine Breast cancer Cell Line Tumor Internal medicine medicine Animals Humans Cell Proliferation Oncogene Cell growth Cancer Middle Aged Cell cycle Prognosis medicine.disease Molecular medicine Up-Regulation Gene Expression Regulation Neoplastic 030104 developmental biology medicine.anatomical_structure Gene Knockdown Techniques 030220 oncology & carcinogenesis Cancer research Female Neoplasm Transplantation |
| Zdroj: | International Journal of Oncology. 48:2015-2024 |
| ISSN: | 1791-2423 1019-6439 |
| DOI: | 10.3892/ijo.2016.3408 |
| Popis: | Breast cancer is the most prevalent type of cancer among women. CD59, a membrane complement regulatory protein, has been demonstrated to be overexpressed in most solid tumors, where it facilitates tumor cell escape from complement surveillance. However, the role of CD59 in breast cancer growth and clinical prognosis is not fully revealed. To investigate the role of CD59 in breast cancer growth and prognostic significance, we knocked down CD59 in a breast cancer cell line that is highly metastatic to the lungs, MDA-MB‑231-HM. Cell growth was measured in vitro and in vivo using a xenograft model. In addition, clinical data on a cohort of 120 patients with or without lung metastasis was analyzed based on CD59 expression, which was detected by immunohistochemistry. Knockdown of CD59 significantly inhibited MDA-MB‑231-HM cell growth both in vitro and in vivo. An analysis of clinical data on 120 patients revealed that patients with CD59 overexpression may have a worse prognosis. CD59 may therefore be a prognostic biomarker for poor outcome in breast cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|